DL Eisenberg, CB Toris, CB Camras - Survey of ophthalmology, 2002 - Elsevier Bimatoprost (Lumigan™ [Allergan, Inc, Irvine CA]) and travoprost (Travatan™
[Alcon, Ft Worth, TX]) are two new intraocular pressure (IOP)-lowering drugs for
use in patients with glaucoma and ocular hypertension. This review ... Cited by 59 - Related articles - All 13 versions
N Orzalesi, L Rossetti, A Bottoli, P Fogagnolo - Ophthalmology, 2006 - Elsevier To compare 24-hour reduction in intraocular pressure (IOP) by latanoprost
0.005%, travoprost 0.004%, and bimatoprost 0.03% in patients with primary
open-angle glaucoma (POAG) or ocular hypertension (OH). Cited by 45 - Related articles - All 14 versions
P Denis, A Lafuma, B Khoshnood, V Mimaud, … - Current Medical Research and Opinion®, 2007 - informahealthcare.com Ph. denisa, A. lafumab, b. Khoshnoodc, V. Mimaudb and G. berdeauxc,d ...
Address for correspondence: Gilles Berdeaux, MD, Alcon France, 4, rue Henri
Sainte‑Claire Deville, F‑92563 Rueil‑Malmaison Cedex, France. Tel.: ... Cited by 19 - Related articles - BL Direct - All 5 versions
- ►nih.gov K Kashiwagi, S Tsukahara - British Journal of Ophthalmology, 2003 - bjo.bmj.com Methods: This study was conducted as a prospective and observer masked clinical
trial. 13 normal volunteers were enrolled. After measurement of basal IOP and
ophthalmic examination, latanoprost ophthalmic solution was initially ... Cited by 13 - Related articles - BL Direct - All 8 versions
- ►nih.gov TYY Lai, VWY Wong, GM Leung - British Journal of Ophthalmology, 2003 - bjo.bmj.com Results: A total of 274 consecutive consultation episodes were examined. 22
cases were excluded since no diagnosis or intervention was made during the
consultation. 108 (42.9%) patient interventions were found to be based on ... Cited by 13 - Related articles - BL Direct - All 9 versions
M Diestelhorst, JP Nordmann, CB Toris - Survey of ophthalmology, 2002 - Elsevier Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as
one-third of all patients being treated for glaucoma need additional therapy to
reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are ... Cited by 11 - Related articles - All 13 versions
N Ishida, N Odani-Kawabata, A Shimazaki, H … - Cardiovascular drug reviews, 2006 - interscience.wiley.com Elevated intraocular pressure (IOP) is one of the most important risk factors
for the development of glaucoma, which is a progressive optic neuropathy.
Lowering IOP is currently the only therapeutic approach to the therapy of ... Cited by 11 - Related articles - BL Direct - All 4 versions
- ►nih.gov HD Pomeranz - British Medical Journal, 2006 - bjo.bmj.com (1663 articles) Neurology (429 articles) Optic nerve (319 articles) Public
health ... Articles on similar topics can be found in the following collections ... ............................................................... ....... ... Cited by 9 - Related articles - BL Direct - All 7 versions
ZK Johnson, PG Griffiths, MK Birch - Eye, 2003 - nature.com Results A total of 46 patients were commenced on treatment at the clinic, 31 on
timolol, 14 on latanoprost, and one on brimonidine. Four of these had the
treatment stopped at the review clinic in order to reassess the diagnosis. ... Cited by 5 - Related articles - BL Direct - All 4 versions
